MAP2K7 and biliary tract neoplasm: To date, clinical trials with targeted therapies for advanced biliary tract cancers have failed to produce significant benefits [11], and ongoing studies are exploring the combination of chemotherapy with novel MAPK/ERK Kinase (MEK) and mTOR inhibitors [40].